Related Experiment Video

Updated: Dec 25, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K

DLX6 Antisense RNA 1 Modulates Glucose Metabolism and Cell Growth in Gastric Cancer by Targeting microRNA-4290

Yan Qian1, Wei Song2, Xu Wu1

  • 1Department of Gastric, The Affiliated Huaian N0.1 People's Hospital of Nanjing Medical University, No. 1 Huanghe West Road, Huaiyin District, Huai'an City, 223300, Jiangsu Province, China.

Digestive Diseases and Sciences
|April 3, 2020
PubMed
Abstract

Insights

Long noncoding RNA DLX6-AS1 promotes gastric cancer (GC) progression by affecting cell viability, apoptosis, and metabolism. Targeting DLX6-AS1 offers a potential therapeutic strategy for gastric cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Gastric cancer (GC) is a prevalent malignancy globally.
  • Long noncoding RNA DLX6-AS1 (DLX6-AS1) is implicated as an oncogene in various human carcinomas.
  • The specific role of DLX6-AS1 in GC progression requires elucidation.

Purpose of the Study:

  • To investigate the regulatory role of DLX6-AS1 in gastric cancer progression.
  • To explore the molecular mechanisms underlying DLX6-AS1's function in GC.

Main Methods:

  • Examined DLX6-AS1 expression in GC tissues and cell lines.
  • Assessed cell viability, colony formation, apoptosis, aerobic glycolysis, and mitochondrial respiration.
  • Evaluated the effect of DLX6-AS1 on tumor growth in a mouse xenograft model.

Main Results:

  • DLX6-AS1 was overexpressed in GC tissues and cell lines.
  • DLX6-AS1 knockdown inhibited cell viability and colony formation, induced apoptosis, impaired aerobic glycolysis, and stimulated mitochondrial respiration.
  • DLX6-AS1 targeted miR-4290, which in turn regulated PDK1; DLX6-AS1 knockdown suppressed tumor growth in vivo.

Conclusions:

  • DLX6-AS1 promotes gastric cancer growth and alters cellular metabolism by targeting miR-4290 and PDK1.
  • DLX6-AS1 represents a potential therapeutic target for gastric cancer treatment.
Keywords:
DLX6-AS1Gastric cancerLong noncoding RNAPDK1miR-4290microRNA

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.9K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
755
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.6K